• Bloomberg


Takeda Pharmaceutical Co., Japan’s largest drugmaker, agreed to buy the local unit of Amgen Inc., gaining cancer and arthritis medicines.

The financial terms include an upfront cash payment to Amgen of $200 million, the companies said in a statement Monday.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.